Results 221 to 230 of about 122,879 (287)

Expert Perspective: Diagnostic Approach to Differentiating Juvenile Dermatomyositis From Muscular Dystrophy

open access: yesArthritis &Rheumatology, EarlyView.
Clinical tools that can aid in the diagnostic differentiation of juvenile dermatomyositis from muscular dystrophy.
Jacqueline A. Madison   +9 more
wiley   +1 more source

Efficacy and Safety of Subcutaneous Abatacept Plus Standard Treatment for Active Idiopathic Inflammatory Myopathy: Phase 3 Randomized Controlled Trial

open access: yesArthritis &Rheumatology, EarlyView.
Objective Our objective was to evaluate the efficacy and safety of subcutaneous (SC) abatacept and standard of care (SOC) for the treatment of idiopathic inflammatory myopathy (IIM) over 52 weeks. Methods In this randomized, double‐blind, placebo‐controlled phase III trial, patients with treatment‐refractory IIM received SC abatacept (at 125 mg weekly)
Rohit Aggarwal   +5 more
wiley   +1 more source

Proteomic Profiling of the Large‐Vessel Vasculitis Spectrum Identifying Shared Signatures of Innate Immune Activation and Stromal Remodeling

open access: yesArthritis &Rheumatology, EarlyView.
Objective Takayasu arteritis (TAK) and giant cell arteritis (GCA), the most common forms of large‐vessel vasculitis (LVV), can result in serious morbidity. Understanding the molecular basis of LVV should aid in developing better biomarkers and treatments. Methods Plasma proteomic profiling of 184 proteins was performed in two cohorts. Cohort 1 included
Robert T. Maughan   +15 more
wiley   +1 more source

Sustained IFN Signature Suppression with Anifrolumab in a SAVI patient Refractory to JAK Inhibitor and Dazukibart Therapy

open access: yesArthritis &Rheumatology, Accepted Article.
Objective To report the efficacy and safety of interferon‐β (IFNβ) neutralizing monoclonal antibody (dazukibart), followed by treatment with anti‐IFNAR1 antibody (anifrolumab), in a patient with STING‐associated vasculopathy with onset in infancy (SAVI) who had vasculitic ulcers and systemic inflammation refractory to Janus kinase inhibition (JAKi ...
Sara Alehashemi   +13 more
wiley   +1 more source

Comparative toxicity of non-steroidal anti-inflammatory agents

open access: bronze, 1994
Gurkirpal Singh   +3 more
openalex   +1 more source

Effects of secukinumab on enthesiophyte and erosion progression in psoriatic arthritis –a one‐year double‐blind, randomized, placebo‐controlled trial utilizing high‐resolution peripheral quantitative computed tomography

open access: yesArthritis &Rheumatology, Accepted Article.
Objectives This study aimed to ascertain the effect of secukinumab on erosion and enthesiophyte progression in psoriatic arthritis (PsA) by high‐resolution peripheral quantitative computed tomography (HR‐pQCT). Methods This was a phase 4, double‐blind, randomized, placebo‐controlled trial.
Yingzhao Jin   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy